1 |
GRIA1
| [14] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
2 |
GRIA2
| [15] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
3 |
GRIA3
| [13] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
4 |
GRIA4
| [10] cAMP signaling pathway cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
5 |
GRIK1
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
6 |
GRIK2
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
7 |
GRIK3
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
8 |
GRIK4
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
9 |
GRIK5
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Glutamatergic synapse | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
10 |
GRIN1
| [18] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
11 |
GRIN2A
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
12 |
GRIN2B
| [19] Ras signaling pathway Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
13 |
GRIN2C
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |
14 |
GRIN2D
| [15] Calcium signaling pathway Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism | D00775
D00775
|
Riluzole
| [9] 2 2, 3, 5, 8, 13, 17, 18, 203, 206 |